547 related articles for article (PubMed ID: 24814528)
21. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
Zacchè MM; Caputo L; Filippis S; Zacchè G; Dindelli M; Ferrari A
Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
[TBL] [Abstract][Full Text] [Related]
22. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Karakoç A; Törüner F; Bingöl B; Cakir N; Tiras B; Ayvaz G; Arslan M
J Endocrinol Invest; 2005 Dec; 28(11):1003-8. PubMed ID: 16483179
[TBL] [Abstract][Full Text] [Related]
23. Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome.
Oner G; Muderris II
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):127-31. PubMed ID: 21831508
[TBL] [Abstract][Full Text] [Related]
24. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome.
Ardawi MS; Rouzi AA
Fertil Steril; 2005 Jun; 83(6):1708-16. PubMed ID: 15950640
[TBL] [Abstract][Full Text] [Related]
25. Melatonin Treatment May Be Able to Restore Menstrual Cyclicity in Women With PCOS: A Pilot Study.
Tagliaferri V; Romualdi D; Scarinci E; Cicco S; Florio CD; Immediata V; Tropea A; Santarsiero CM; Lanzone A; Apa R
Reprod Sci; 2018 Feb; 25(2):269-275. PubMed ID: 28558523
[TBL] [Abstract][Full Text] [Related]
26. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome.
Belli SH; Graffigna MN; Oneto A; Otero P; Schurman L; Levalle OA
Fertil Steril; 2004 Mar; 81(3):624-9. PubMed ID: 15037412
[TBL] [Abstract][Full Text] [Related]
27. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome.
Tarkun I; Cetinarslan B; Türemen E; Sahin T; Cantürk Z; Komsuoglu B
Eur J Endocrinol; 2005 Jul; 153(1):115-21. PubMed ID: 15994753
[TBL] [Abstract][Full Text] [Related]
28. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
[TBL] [Abstract][Full Text] [Related]
29. Treatment options of polycystic ovary syndrome in adolescence.
Zapanti E; Kiapekou E; Loutradis D
Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():208-13. PubMed ID: 16641862
[TBL] [Abstract][Full Text] [Related]
30. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome.
Arikan S; Bahceci M; Tuzcu A; Kale E; Gökalp D
Gynecol Endocrinol; 2010 Mar; 26(3):161-6. PubMed ID: 20148738
[TBL] [Abstract][Full Text] [Related]
31. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
32. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.
Glintborg D; Hermann AP; Andersen M; Hagen C; Beck-Nielsen H; Veldhuis JD; Henriksen JE
Fertil Steril; 2006 Aug; 86(2):385-97. PubMed ID: 16782094
[TBL] [Abstract][Full Text] [Related]
33. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106
[TBL] [Abstract][Full Text] [Related]
34. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
35. Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment.
Aigner E; Bachofner N; Klein K; De Geyter C; Hohla F; Patsch W; Datz C
J Clin Endocrinol Metab; 2009 Apr; 94(4):1229-35. PubMed ID: 19158194
[TBL] [Abstract][Full Text] [Related]
36. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
[TBL] [Abstract][Full Text] [Related]
38. Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance.
Morishita M; Endo T; Baba T; Kuno Y; Ikeda K; Kiya T; Honnma H; Saito T
J Ovarian Res; 2018 Mar; 11(1):24. PubMed ID: 29580285
[TBL] [Abstract][Full Text] [Related]
39. Metformin therapy in women with polycystic ovary syndrome.
Aruna J; Mittal S; Kumar S; Misra R; Dadhwal V; Vimala N
Int J Gynaecol Obstet; 2004 Dec; 87(3):237-41. PubMed ID: 15548396
[TBL] [Abstract][Full Text] [Related]
40. [Interrelationship of abnormal family history in the first degree relatives and clinical phenotype of patients with polycystic ovary syndrome].
Wang Y; Mao WW; Chen YJ; Li MZ; Qiao J; Wang LN
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):756-60. PubMed ID: 18307903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
